X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AOC 1001 (Del-desiran) consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK mRNA. It is being evaluated for the treatment of myotonic dystrophy type 1.
Lead Product(s): Del-desiran
Therapeutic Area: Genetic Disease Product Name: AOC 1001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Avidity intends to use the net proceeds from the private placement to fund research and development of its clinical-stage product candidate AOC 1001, designed to reduce the levels of DMPK mRNA for the treatment of myotonic dystrophy type 1.
Lead Product(s): AOC 1001
Therapeutic Area: Genetic Disease Product Name: AOC 1001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Adage Capital Partners LP
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 29, 2024
Details:
AOC 1044 is designed to deliver phosphorodiamidate morpholino oligomers to skeletal muscle and heart tissue. It is being evaluated for treatment of duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping.
Lead Product(s): AOC 1044
Therapeutic Area: Genetic Disease Product Name: AOC 1044
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The collaboration aims to focus on discovery, development and commercialization of up to five cardiovascular targets by leveraging Avidity's proprietary AOC platform technology, to deliver a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates.
Lead Product(s): RNA Therapeutic
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $2,275.0 million Upfront Cash: $100.0 million
Deal Type: Collaboration November 28, 2023
Details:
AOC 1001 consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK mRNA. It is being investigated for myotonic dystrophy type 1.
Lead Product(s): AOC 1001
Therapeutic Area: Genetic Disease Product Name: AOC 1001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2023
Details:
AOC 1044 is designed to deliver phosphorodiamidate morpholino oligomers to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene to enable dystrophin production in people living with Duchenne muscular dystrophy.
Lead Product(s): AOC 1044
Therapeutic Area: Genetic Disease Product Name: AOC 1044
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
AOC 1001 consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK mRNA. It is being investigated for myotonic dystrophy type 1.
Lead Product(s): AOC 1001
Therapeutic Area: Genetic Disease Product Name: AOC 1001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
AOC 1001 consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DMPK mRNA. It is being investigated for myotonic dystrophy type 1.
Lead Product(s): AOC 1001
Therapeutic Area: Genetic Disease Product Name: AOC 1001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
AOC 1044 is designed to deliver phosphorodiamidate morpholino oligomers to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene to enable dystrophin production in patients with DMD, with mutations amenable to exon 44 skipping.
Lead Product(s): AOC 1044
Therapeutic Area: Genetic Disease Product Name: AOC 1044
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
AOC 1020 consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 mRNA to reduce the expression of DUX4 mRNA and DUX4 protein in muscles in patients with FSHD.
Lead Product(s): AOC 1020
Therapeutic Area: Musculoskeletal Product Name: AOC 1020
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
